Daily administration rates of #COVID-19 #vaccines in EU countries show that countries that have languished near the… https://t.co/IpgEDifFxA
Customer Logins
Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Customer LoginsOur pricing and reimbursement research presented at ISPOR Europe

In research, presented at the ISPOR Europe meeting in Barcelona on 13 October, Associate Director Milena Izmirlieva examines the impact of securing marketing approval under an expedited pathway on pricing and reimbursement outcomes.
Related Posts
-
EU countries make inroads in COVID-19 vaccination race even as supply concerns linger -
COVID19 Research and Development Tracker: Vaccine rollouts, dosing controversies and new strains -
ESG criteria in tendering landscape shows wide variation between top-5 European countries -
Market access in China: An increasingly dynamic environment -
Pfizer and BioNTech's COVID-19 vaccine -
Mixed news on COVID19 vaccines: COVID-19 R&D tracker -
Innovation in Japan’s regenerative sector -
US drug prices could be drastically impacted by Most Favored Nation executive order
Explore
RELATED INDUSTRIES & TOPICS
Follow Us
Using our #Covid-19 R&D tracker we take stock of several key developments as the world battles new strains of the v… https://t.co/YPh239aSvq
Our ProcureIntel tender analysis highlights growing space for the inclusion of ESG criteria for in the top-5 Europe… https://t.co/xqkWQrIcUY
China’s massive investment in biotech over the last couple of years has the potential to be a gamechanger for multi… https://t.co/DsbxEUtzRb